semaglutide nash phase 3 and lanifibranor differentially improves quantitative A Placebo-Controlled Trial of Subcutaneous

That makes it effective for treating obesity and diabetes, but this boost in biological regulation seems to have plenty of other benefits too

The reduction of inflammatory signaling may play an additional role in the analgesic effects of GLP-1R agonists against neuropathic pain [32, 34, 35]

However, its also essential to consider the overall value of each medication, including the potential weight loss outcomes and the likelihood of side effects

Further reading:

This broader application of semaglutide underscores its versatility and potential to improve patient outcomes in various metabolic conditions

Semaglutides impact on asthma exacerbation rates in patients with comorbid obesity: A cohort study